Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.80 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 9/20 | 0.64 |
| ▸ | ITGB8 | P26012 | 9/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442229 | 1.00 | ITGAV (0.80) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL5824333 | 1.00 | ITGAV (0.80) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL5254889 | 0.97 | ITGAV (0.76) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL5254905 | 0.97 | ITGAV (0.76) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL5255492 | 0.97 | ITGAV (0.76) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL7441291 | 0.91 | ITGAV (0.81) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL7443940 | 0.91 | ITGAV (0.81) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL7439662 | 0.91 | ITGAV (0.81) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL7433549 | 0.91 | ITGAV (0.81) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL7436004 | 0.91 | ITGAV (0.66) | ITGAVITGB3ITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | ITGAM, ITGAL, ITGB1 | ITGAV 9/4885ITGB3 8/4885ITGB5 10/4885 |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.